Program Announcement:

Cancer Moonshot Initiative on Retrospective Characterization of Biospecimens from NCI-sponsored NCTN and NCORP Trials 


Dear NRG Oncology Membership,

Please see the message from the National Cancer Institute (NCI) at the link below regarding the NCI Molecular Profiling to Predict Response to Treatment (MP2PRT) Program: Retrospective Characterization and Analysis of Biospecimens Collected from NCI-Sponsored Trials of the NCTN and NCORP Focused on Adult Cancers.

"The NCI invites funded NCTN Network Groups (NCTN Operations Centers in conjunction with the NCTN Biospecimen Banks, NCTN Statistics & Data Management Centers (SDMCs), and relevant group of NCTN investigators) and NCORP Research Bases to submit proposals requesting characterization of biospecimens collected from NCI-sponsored NCTN or NCORP clinical trials in adult cancers in which clinical data have already been presented or published, or for which publication or presentation at a major scientific meeting is planned by December 31, 2019. The MP2PRT seeks proposals that are hypothesis-driven, hypothesis-generating, or exploratory in a specific adult population, and that propose studies wherein comprehensive molecular analyses could answer a key clinical question." More information

If you are considering or intending on applying for this program, please contact Chery Vogrig at ASAP conveying your interest.


Click here to download the announcement from the NCI



View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.
This message was sent from to
Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103

Update Profile/Email Address | Forward Email | Report Abuse